Cabaletta Bio (CABA) analyst forecast and price target
Analyst forecast
Consensus of 10 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wells Fargo | Maintained | Equal-Weight | $3.00 from $4.00 | Aug 14, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $4.00 from $2.00 | May 15, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $30.00 | May 4, 2026 |
| Guggenheim | Maintained | Buy | $16.00 from $15.00 | Mar 24, 2026 |
| Morgan Stanley | Maintained | Overweight | $13.00 from $14.00 | Mar 24, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $30.00 from $15.00 | Oct 31, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $16.00 | Oct 10, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | $15.00 | Sep 5, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $2.00 from $3.00 | Aug 8, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Jun 11, 2025 |
| Guggenheim | Maintained | Buy | $25.00 from $23.00 | May 16, 2025 |
| Citigroup | Maintained | Buy | $13.00 from $17.00 | May 16, 2025 |
| Guggenheim | Maintained | Buy | $25.00 from $23.00 | May 15, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Apr 1, 2025 |
| Morgan Stanley | Maintained | Overweight | $22.00 from $30.00 | Apr 1, 2025 |
| UBS | Maintained | Buy | $7.00 from $10.00 | Apr 1, 2025 |
| Guggenheim | Maintained | Buy | $23.00 | Apr 1, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $3.00 from $6.00 | Apr 1, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Feb 18, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Jan 17, 2025 |
Frequently asked questions
Is CABA a buy, sell, or hold?
Analysts covering Cabaletta Bio currently average a Buy rating: 8 buy, 2 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on CABA?
On Aug 14, 2026, Wells Fargo maintained Cabaletta Bio at Equal-Weight with a price target of $3.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.